Clinical Profile of Hepatorenal Syndrome: A Prospective Study


  • Dayanand Medical College, Ludhiana, India
  • Punjab Institute of Medical Sciences, Jalandhar, Punjab, India
  • Dayanand Medical College and Hospital, Ludhiana, Punjab, India


Background: Hepatorenal syndrome is the development of renal failure in patients with advanced liver cirrhosis, occasionally fulminant hepatitis, who have portal hypertension and ascitis in the absence of some other kidney disease.

Objective: To study the clinical profile of hepatorenal syndrome.

Methods: All patients of chronic liver disease with renal involvement were studied and patients fulfilling the criteria of hepatorenal syndrome were recruited in the study. The etiology, clinical presentation, morbidity and outcome of patients were recorded. Various variables were studied between survivor group and non survivor group to detect possible predictors of non survival in hepatorenal syndrome. The data was analyzed using SPSS software.

Results: 42 patients of hepatorenal syndrome were clinically evaluated. 95% were males and 5% females with mean age of 50.29 ± 8.87 in survivor group and 45.92 ± 10.1 in non survivor group. High level of serum bilirubin, hepatic encephalopathy, decreased level of albumin, hyponatremia and coagulopathy were significant in non survivor group as compared to survivor group.

Conclusion: The poor prognostic factors were found to be ascites, severe jaundice, hepatic encephalopathy, alcohol abuse, hypoalbuminemia, progressive renal failure and child pugh score greater than 10. Thus hepatorenal syndrome is decompensated cirrhosis which needs judicious treatment especially using terlipressin and albumin.


Hepatorenal Syndrome, Profile, Jaundice, Child Pugh Score, Ascitis, Albumin.

Subject Discipline

Urology and Nephrology

Full Text:


Arroyo V, Gines P, Jimenez W. Renal dysfunction in cirrhosis. In: Bricher J, Benhamou J, McIntyre N, Rizzetto M, Rodes J, editors. Oxford textbook of clinical hepatology. 2nd ed. England: Oxford university press; 1999. p. 733-61.

Epstein M. Hepatorenal syndrome. Emerging perspectives of pathophysiology and therapy. J Am Soc Nephro 1994; 14:1735-53.

Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 1993; 105:229-36.

Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56(9):1310-8.

Lata J. Hepatorenal syndrome. World Journal of Gastroenterology 2012; 36(18):4978-84.

Butt AK, Khan AA, Alam A, Shah SW, Shafqat F, Naqvi AB. Predicting hospital mortality in cirrhotic patients: comparision of child Pugh and acute physiology, age and chronic health evaluation scoring systems. Am J Gastroenterol 1998; 93(12):2489-75.

Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Hepatology 1987; 7:122-8.

Salerno F, Borroni G, Moser P, Badalamenti S, Cassara L, Maggi A, et al. Survival and prognostic factors of cirrhotic patients with ascitis: a study of 134 out patients. Am J Gastroenterol 1993; 88:514-19.

Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical features and outcome in a tertiary care center. Am J Gastroenterol 2002; 97(8):1868-70.

Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barriere E, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. Gastrenterol Hepato 2002; 17(18):882-8.

Moreau R, Durand F, Poynard T. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 6:2160-1.


  • There are currently no refbacks.